Analysis of plasma free amino acid profiles in canine brain tumors

Utsugi, Shinichi; Aso, Kazuo; Osaki, Tomohiro; Murahata, Yusuke; Tsuka, Takeshi; Ito, Norihiko; Imagawa, Tomohiro; Okamoto, Yoshiharu

doi:10.3892/br.2016.825

Cited by 8 publications

(11 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Metabolites, including amino acids, can be altered in both neoplastic tissues 23,24 and plasma. 7,[10][11][12][13][14][15][16]18 Alterations in amino acid profiles and protein metabolism can reflect the effect of pathogenic changes because tumor development and growth require amino acids for protein synthesis, and both local and circulating amino acids are critical sources of metabolic fuel, leading to an increase in the mass of the affected tissue. 11,23 Previous studies in humans have suggested that some amino acids and liver function indicators, including Fischer's ratio and BTR, are associated with HCC metabolism.…”

Section: Discussionmentioning

confidence: 99%

Plasma‐free amino acid profiles in dogs with hepatocellular carcinoma

Leela-Arporn

Ohta

Tamura

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

Background Metabolomic analysis using blood samples has been suggested to be useful for the early detection of cancer. Among metabolites, plasma‐free amino acid (PFAA) profiles are potential diagnostic biomarkers for several diseases including cancer. However, the relationship between PFAA concentrations and liver tumors in dogs remains unknown. Objective To determine the characteristics of PFAA profiles of dogs with hepatocellular carcinoma (HCC) and correlated clinical features. Animals Thirty‐four client‐owned dogs diagnosed with HCC (n = 26) and benign liver diseases (n = 8) and 11 age‐matched healthy dogs. Methods Prospective study using heparinized blood samples from fasted dogs. Plasma was deproteinized, and the concentrations of 21 amino acids were measured using an automated high‐performance liquid chromatography amino acid analyzer. Results Plasma glutamic acid concentrations were significantly different among groups ( P < .0024 after Bonferroni correction). Compared to healthy dogs, dogs with HCC and benign liver diseases had significantly higher concentrations of glutamic acid by post hoc analysis. However, no significant difference in the PFAA profiles of HCC and benign liver diseases were detected. In addition, preoperative and postoperative PFAA profiles of dogs with HCC were not significantly different. Conclusions and Clinical Importance Increased glutamic acid concentrations might play a role in the development or be a consequence of liver tumor formation. However, PFAA profiles of HCC could not be differentiated from those of benign lesions. In addition, glutamic acid concentrations did not change after surgical resection. These results indicate that PFAA profiles may not be useful biomarkers for detecting HCC in dogs.

show abstract

Section: Discussionmentioning

confidence: 99%

Plasma‐free amino acid profiles in dogs with hepatocellular carcinoma

Leela-Arporn

Ohta

Tamura

et al. 2019

Veterinary Internal Medicne

View full text Add to dashboard Cite

show abstract

“…Liquid biopsy is a technique for sampling and analyzing non-solid biological tissues, and is mainly used to diagnose disease or monitor therapy. Serum or plasma compounds such as VEGF, glial fibrillary acidic protein, plasma free amino acid profiles, and CSF concentrations of uric acid, D-dimers, and MMP-2 and MMP-9 have been quantified in dogs with brain tumors, but results to date suggest that these compounds will not fulfill ideal biomarker criteria due to limitations associated with sensitivity and specificity (59–65).…”

Section: Diagnosis Of Intracranial Tumorsmentioning

confidence: 99%

Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors

2019

View full text Add to dashboard Cite

In the dog, primary intracranial neoplasia represents ~2–5% of all cancers and is especially common in certain breeds including English and French bulldogs and Boxers. The most common types of primary intracranial cancer in the dog are meningioma, glioma, and choroid plexus tumors, generally occurring in middle aged to older dogs. Much work has recently been done to understand the characteristic imaging and clinicopathologic features of these tumors. The gross and histologic landscape of these tumors in the dog compare favorably to their human counterparts with many similarities noted in histologic patterns, subtype, and grades. Data informing the underlying molecular abnormalities in the canine tumors have only begun to be unraveled, but reveal similar pathways are mutated between canine and human primary intracranial neoplasia. This review will provide an overview of the clinicopathologic features of the three most common forms of primary intracranial cancer in the dog, delve into the comparative aspects between the dog and human neoplasms, and provide an introduction to current standard of care while also highlighting novel, experimental treatments that may help bridge the gap between canine and human cancer therapies.

show abstract

“…The present case showed increased 18F-FDOPA metabolism and revealed strongly diffuse immunoreactivity for LAT1. In veterinary medicine, immunoreactivity for LAT1 in meningiomas was evaluated in only two dogs and two brain samples showed negative or weakly positive reactions for LAT1, previously (28). This is the first case in canine meningioma to show marked immunoreactivity for LAT1, 18F-FDOPA uptake, and suggests that LAT1 may be a molecular target for diagnostic PET imaging and a therapeutic target for canine meningioma.…”

Section: Discussionmentioning

confidence: 74%

Case Report: 18F-Fluoro-L-Phenylalanine Positron Emission Tomography Findings and Immunoreactivity for L-Type Amino Acid Transporter 1 in a Dog With Meningioma

et al. 2022

View full text Add to dashboard Cite

A 12-year-old intact female Miniature Pinscher dog weighing 5.4 kg presented with a history of seizures. On neurological examination, postural reactions were decreased in the left-sided limbs, and menace responses were bilaterally absent. Magnetic resonance imaging (MRI) of the brain was performed, and a solitary amorphous mass (2.7 × 1.9 × 2.2 cm) was observed on the right side of the frontal lobe. Based on the signalment, clinical signs, and MRI findings, a brain tumor was tentatively diagnosed, and meningioma was suspected. The dog was treated with hydroxyurea, prednisolone, and other antiepileptic drugs. One week after the treatment began, postural reactions returned to normal, and the menace response improved. At 119 days after treatment, 18F-fluoro-L-phenylalanine (18F-FDOPA) positron emission tomography (PET) was performed. Marked 18F-FDOPA uptake was observed in the lesion. The mean and maximal standardized uptake values of the lesion were 2.61 and 3.72, respectively, and the tumor-to-normal tissue ratio was 1.95. At 355 days after the initial treatment, a second MRI scan was performed and the tumor size had increased to 3.5 × 2.8 × 2.9 cm. The dog died 443 days after the initial treatment and was definitively diagnosed with grade 1 meningioma by histopathological examination. Immunohistochemical staining for Ki67 and L-type amino acid transporter 1 was positive and negative for p53, respectively. The labeling index of Ki67 was 2.4%. This is the first case to demonstrate 18F-FDOPA PET findings in a clinical case of a dog histologically diagnosed with a meningioma.

show abstract

Analysis of plasma free amino acid profiles in canine brain tumors

Cited by 8 publications

References 21 publications

Plasma‐free amino acid profiles in dogs with hepatocellular carcinoma

Plasma‐free amino acid profiles in dogs with hepatocellular carcinoma

Canine Primary Intracranial Cancer: A Clinicopathologic and Comparative Review of Glioma, Meningioma, and Choroid Plexus Tumors

Case Report: 18F-Fluoro-L-Phenylalanine Positron Emission Tomography Findings and Immunoreactivity for L-Type Amino Acid Transporter 1 in a Dog With Meningioma

Contact Info

Product

Resources

About